Published in Cancer Treat Rep on February 01, 1982
Are reduced quinones necessarily involved in the antitumour activity of quinone drugs? Br J Cancer Suppl (1987) 0.88
Activities of free radical metabolizing enzymes in tumours. Br J Cancer (1983) 0.82
Thiol oxidation coupled to DT-diaphorase-catalysed reduction of diaziquone. Reductive and oxidative pathways of diaziquone semiquinone modulated by glutathione and superoxide dismutase. Biochem J (1992) 0.80
A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res (1978) 2.24
Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer (1974) 2.10
NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci U S A (1979) 1.75
Bis-benzimidazole anticancer agents: targeting human tumour helicases. Anticancer Drug Des (1999) 1.66
Cytofluorescence localization of adriamycin and daunorubicin. Cancer Res (1974) 1.62
Biological and biochemical properties of Phaseolus vulgaris isolectins. J Biol Chem (1977) 1.55
Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J Biol Chem (1984) 1.54
Purification of the phytohemagglutinin family of proteins from red kidney beans (Phaseolus vulgaris) by affinity chromatography. Biochim Biophys Acta (1975) 1.52
Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res (1977) 1.36
Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods. Cancer Chemother Rep (1970) 1.26
Rickettsia rickettsii induces superoxide radical and superoxide dismutase in human endothelial cells. Infect Immun (1992) 1.23
Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol (1977) 1.22
Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther (1973) 1.19
Hepatic stimulator substance: physicochemical characteristics and specificity. Am J Physiol (1982) 1.18
Cytoplasmic aldo-keto reductases: a class of drug metabolizing enzymes. Science (1976) 1.16
The pharmacokinetics of daunomycin in man. Clin Pharmacol Ther (1971) 1.16
Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metab Dispos (1976) 1.14
Free radical increases in cancer: evidence that there is not a real increase. Science (1977) 1.11
Thioredoxin reductase mediates cell death effects of the combination of beta interferon and retinoic acid. Mol Cell Biol (1998) 1.06
An o-quinone form of estrogen produces free radicals in human breast cancer cells: correlation with DNA damage. Chem Res Toxicol (1994) 1.02
Rat liver daunorubicin reductase. An aldo-keto reductase. J Biol Chem (1974) 0.99
Daunomycin metabolism in rat tissue slices. J Pharmacol Exp Ther (1970) 0.99
Adriamycin and daunorubicin disposition in the rabbit. J Pharmacol Exp Ther (1974) 0.99
Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography. Drug Metab Dispos (1980) 0.96
Paramagnetic changes in cancer: DMBA-induced tumours studied in non-lyophilized and lyophilized tissues. Br J Cancer (1979) 0.96
DNA strand scission and free radical production in menadione-treated cells. Correlation with cytotoxicity and role of NADPH quinone acceptor oxidoreductase. J Biol Chem (1992) 0.95
Acute doxorubicin toxicity. Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia. Cancer (1984) 0.95
Nuclear catalyzed antibiotic free radical formation. Cancer Res (1982) 0.95
Microsomal synthesis of fatty acid amides. J Biol Chem (1966) 0.95
Rat liver aldehyde reductase. Biochem Pharmacol (1977) 0.95
Cis-Dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms. Cancer (1980) 0.94
Quantitation with an automated image analyzer of nuclearcytoplasmic changes induced by hydrocortisone in bladder epithelium. Cancer Res (1977) 0.93
Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia. Cancer Res (1972) 0.91
Daunorubicinol, a major metabolite of daunorubicin: isolation from human urine and enzymatic reactions. J Pharmacol Exp Ther (1971) 0.90
Comparison of four different silver-staining techniques for salivary protein detection in alkaline polyacrylamide gels. Anal Biochem (1982) 0.90
A soluble dihydrofolate reductase from human placenta: purification and properties. Arch Biochem Biophys (1971) 0.89
Recombinations of subunits of Phaseolus vulgaris isolectins. J Biol Chem (1977) 0.89
BCL-2 is involved in preventing oxidant-induced cell death and in decreasing oxygen radical production. Redox Rep (2001) 0.89
Daunorubicin metabolism in acute nonlymphocytic leukemia. Clin Pharmacol Ther (1973) 0.88
Paramagnetic changes in cancer: growth of Walker 256 carcinoma studied in frozen and lyophilized tissues. Br J Cancer (1979) 0.88
Induction of a human carbonyl reductase gene located on chromosome 21. Biochim Biophys Acta (1990) 0.87
DNA database searches and the legal consumption of scientific evidence. Mich Law Rev (1997) 0.87
Diurnal variation of circulating human myeloid progenitor cells. Exp Hematol (1980) 0.87
Extracellular serotonin in the lateral hypothalamic area is increased during the postejaculatory interval and impairs copulation in male rats. J Neurosci (1997) 0.87
High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat Rep (1981) 0.86
Organ culture of normal and carcinogen-treated rat bladder. Cancer Res (1976) 0.86
Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res (1978) 0.85
In vitro mechanisms of chemopotentiation by tone-burst ultrasound. Ultrasound Med Biol (1996) 0.84
Reversal by adenosine of ADP inhibition of platelet (Na+ + K+)-ATPase. Biochim Biophys Acta (1970) 0.84
Daunorubicin metabolism by rat tissue preparations. J Pharmacol Exp Ther (1971) 0.84
Heterogeneity of anthracycline antibiotic carbonyl reductases in mammalian livers. Biochem Pharmacol (1978) 0.84
Cytofluorescence localization of anthracycline antibiotics. Cancer Res (1980) 0.84
NAD(P)H (quinone acceptor) oxidoreductase (DT-diaphorase)-mediated two-electron reduction of anthraquinone-based antitumour agents and generation of hydroxyl radicals. Biochem Pharmacol (1992) 0.84
Mammalian carbonyl reductases. Drug Metab Rev (1980) 0.83
Adriamycin and daunorubicin inhibition of mutant T4 DNA polymerases. Proc Natl Acad Sci U S A (1974) 0.83
Alterations in adriamycin efficacy by phenobarbital. Cancer Res (1976) 0.83
Bilary disposition of adriamycin. Clin Pharmacol Ther (1977) 0.83
Doxorubicin and cisplatin excretion into human milk. Cancer Treat Rep (1985) 0.83
Antihelicase action of CI-958, a new drug for prostate cancer. Cancer Chemother Pharmacol (1998) 0.82
Xanthine oxidase catalyzed reductive cleavage of anthracycline antibiotics and free radical formation. Mol Pharmacol (1980) 0.82
DNA alkylation by enzyme-activated mitomycin C. Mol Pharmacol (1986) 0.82
Mechanism for the reductive activation of diaziquone. J Pharm Sci (1985) 0.82
Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys (1983) 0.82
Trace determination of hydroxyl radical in biological systems. Anal Chem (1997) 0.82
Reductive metabolism of diaziquone (AZQ) in the S9 fraction of MCF-7 cells. II. Enhancement of the alkylating activity of AZQ by NAD(P)H: quinone-acceptor oxidoreductase (DT-diaphorase). Biochem Pharmacol (1992) 0.82
Immunological relationships and a genetic interpretation of major and minor acidic proteins in human parotid saliva. Biochem Genet (1977) 0.81
Human salivary proline-rich (Pr) proteins: a posttranslational derivation of the phenotypes. Biochem Genet (1979) 0.81
Comparative flavoprotein catalysis of anthracycline antibiotic. Reductive cleavage and oxygen consumption. Mol Pharmacol (1981) 0.81
A comparison of free radical formation by quinone antitumour agents in MCF-7 cells and the role of NAD(P)H (quinone-acceptor) oxidoreductase (DT-diaphorase). Chem Biol Interact (1993) 0.81
Fragmentation characteristic of glutathione conjugates activated by high-energy collisions. J Am Soc Mass Spectrom (1992) 0.81
Adriamycin: a new effective agent in the therapy of disseminated sarcomas. Med Pediatr Oncol (1975) 0.81
Induction of p53 by the concerted actions of aziridine and quinone moieties of diaziquone. Chem Res Toxicol (1998) 0.81
Heritable salivary proteins and dental disease. Hum Hered (1980) 0.80
Prostaglandin B equivalents in human plasma. Prostaglandins (1974) 0.80
Comparison and characterization of mammalian xenobiotic ketone reductases. J Pharmacol Exp Ther (1979) 0.80
Daunorubicin biliary excretion and metabolism in the rat. Arch Int Pharmacodyn Ther (1973) 0.79
Effects of ascorbic acid on biologically obtained diaziquone free radicals. Biochem Pharmacol (1985) 0.79
Mechanism(s) for the metabolism of mitoxantrone: electron spin resonance and electrochemical studies. Chem Biol Interact (1990) 0.79
Cellular pharmacology of N,N',N''-triethylene thiophosphoramide. Cancer Lett (1988) 0.79
Variation amongst K562 cell cultures. Exp Hematol (1983) 0.79
Daunorubicin metabolism in acute myelocytic leukemia. Blood (1972) 0.79
Modulation of streptonigrin cytotoxicity by nitroxide SOD mimics. Free Radic Biol Med (1994) 0.79
Effects of deoxynucleosides on cultured human leukemia cell growth and deoxynucleotide pools. Cancer Res (1981) 0.79
Alteration of DNA base excision repair enzymes hMYH and hOGG1 in hydrogen peroxide resistant transformed human breast cells. Med Sci Monit (2001) 0.79
Cellular accumulation and disposition of aclacinomycin A. Cancer Res (1979) 0.79
A method for detecting organic acids on thin-layer and paper chromatograms. Anal Biochem (1965) 0.79
Diurnal rhythm: effects on hepatic regeneration and hepatic regenerative stimulator substance. Science (1978) 0.78
Experimental chemotherapy-induced skin necrosis in swine. Mechanistic studies of anthracycline antibiotic toxicity and protection with a radical dimer compound. J Clin Invest (1988) 0.78
Daunorubicin metabolites in human urine. J Pharmacol Exp Ther (1975) 0.78
Doxorubicin-induced skin necrosis in the swine model: protection with a novel radical dimer. J Clin Oncol (1986) 0.78
Letter: Contact dermatitis associated with adriamycin (NSC-123127) and daunorubicin (NSC-82151). Cancer Chemother Rep (1975) 0.78
Reductive activation of diaziquone and possible involvement of free radicals and the hydroquinone dianion. Cancer Res (1986) 0.78
Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma. Cancer Chemother Pharmacol (1982) 0.78
Prevention of adriamycin toxicity. Cancer Chemother Pharmacol (1983) 0.78
Plasma pharmacokinetics and tissue distribution of thiotepa in mice. Cancer Treat Rep (1984) 0.78
Plasma kinetics of aclacinomycin A and its major metabolites in man. Cancer Chemother Pharmacol (1982) 0.78
Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites. Cancer Treat Rep (1986) 0.77